Adamis Pharmaceuticals reported 4.21M in Selling and Administration Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Adamis Pharmaceuticals ADMP:US 4.21M 823.23K
Adma Biologics ADMA:US $ 15.89M 1.78M
Brainstorm Cell Therapeutics BCLI:US $ 2.48M 381K
Cara Therapeutics CARA:US $ 7.54M 1.78M
Cerulean Pharma CERU:US $ 2.59M 168.34K
Glaxosmithkline GSK:US 1.96B 726M
GlaxoSmithKline GSK:LN 195.5B 18.5B
Merk MRK:US $ 2.42B 118M
Pfizer PFE:US $ 3.2B 506M
Redhill Biopharma RDHL:US 20.38M 2.81M